CD79A and COVID-19: The positivity rate for IgA anti-SRBD remained relatively stable over time (65.2–87.5%), while most samples positive for IgM anti-SRBD were detected when those collected occurred 11 to 20 days after the diagnosis of COVID-19 (83.3%), with a reduction in their levels to 62.5%.